tradmap

MRNA Moderna

$147.40 -1.94%

Updated

S&P 500 Companies

Held by SPYVOOIVV

Healthcare · Biological Products, (No Diagnostic Substances)

Moderna (MRNA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $58.8 billion. Shares last traded at $147.40, 24.3% below their 52-week high. Over the past year the stock is up 512.6%. Net profit margin is -141.4%, below the peer median of 5.3%. Revenue declined 39.9% year over year.

Market Cap
$58.8B
Shares Out
399.2M
EPS (TTM)
$-18.55
P/E Ratio
P/S Ratio
26.41
P/B Ratio
8.70
Dividend / Share
Dividend Yield
52-Week High
$194.70
52-Week Low
$22.28
Volume
540,422
Avg Vol (3m)
467,904.683

Performance

1W
+3.50%
1M
+162.18%
3M
+187.33%
6M
+175.21%
YTD
+377.49%
1Y
+512.64%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
65.35
SMA (50)
$83.41
SMA (200)
$54.17
Price vs SMA50
+76.71%
Price vs SMA200
+172.10%
ATR (14)
$14.44

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$2.2B
Net Income
$-3151M
Gross Margin
23.4%
Operating Margin
-149.0%
Net Margin
-141.4%
Return on Equity
-46.6%
Return on Assets
-28.7%
Current Ratio
2.29
Debt / Equity
0.09
Revenue Growth (YoY)
-39.9%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-5.36 2026-07-31
Q1 2026 $-3.40 2026-05-01
FY 2025 $-7.26 2026-02-20
Q3 2025 $-5.15 2025-11-06
Q2 2026 $-4.64 2026-07-31
Q1 2026 $-2.52 2026-05-01

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

MRNA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
26.41 / 19.49 med
+35% premium
Net margin vs peers
-141.4% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.